Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc., a foreign-owned subsidiary of Japan-based Takeda Pharmaceutical Company Limited, supplies specialized biopharmaceutical products to the federal government as a prime contractor on the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), holding no socioeconomic set-aside designations. The company operates from Lexington, Massachusetts and Brooks, Kentucky, competing full-and-open against other pharmaceutical vendors.

Takeda's federal footprint centers on nine therapeutic-area medications addressing rare genetic disorders, hemophilia, immune deficiencies, hereditary angioedema, and short bowel syndrome. Named products include CINRYZE and KALBITOR for hereditary angioedema, ADVATE and OBIZUR for hemophilia management, GAMMAGARD and other immune globulin products for immunological conditions, TAKHZYRO for rare genetic disorders, LIVTENCITY for transplant-related infections, GATTEX for short bowel syndrome, ELAPRASE and VPRIV for rare metabolic conditions, FIRAZYR for acute episodes, and ADZYNMA for hereditary angioedema prevention. Representative recent delivery orders include a $550,608.60 award from Federal Correctional Institution Fort Worth (April 2026) for pharmacy supply covering April through September 2026, a $204,577.58 delivery order from the same facility (February 2026) for pharmacy operations spanning January through September 2026, and a $107,540.16 purchase order from Veterans Integrated Service Network 20 (April 2026) for Gammagard Liquid immune globulin intravenous injection.

Customer concentration diverges sharply between award count and dollar magnitude. By award count, the Department of Justice Bureau of Prisons Federal Correctional Institution Fort Worth dominates with 40 awards (combined potential value $5.6 million), followed by VA facilities including Veterans Integrated Service Network 21 (22 awards, $1.3 million), Veterans Integrated Service Network 20 (14 awards, $1.4 million), and Veterans Integrated Service Network 5 (14 awards, $446 thousand). This top-five set covers 72% of recent awards. By potential value, however, Veterans Integrated Service Network 12 anchors the portfolio at $6.5 billion across just six orders, driven by Takeda's single-award Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.0 million (July 15, 2025, through March 12, 2026, now extended to August 27, 2027, at $231.2 million). The National Acquisition Center itself accounts for $445.5 million across four awards, establishing VA as the overwhelming value driver despite the Fort Worth facility's order-count lead.

Takeda's prime vehicle position concentrates entirely on the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), which generated 130 delivery orders and purchase orders carrying $392.1 million combined potential value. All 141 awards in the recent portfolio are prime contracts; no sub-award activity appears. The company also holds a Federal Supply Schedule contract issued August 15, 2026, with a multi-billion-dollar ceiling through August 14, 2031, and a single-award BPA that operates as a child contract under the GSA pharmaceutical vehicle.

Activity has accelerated year over year from 19 awards in 2022 to a peak of 37 in 2024, with 26 in 2025 and 17 so far in 2026. Only four awards (combined potential value $86 thousand) reach ultimate completion in the next twenty-four months, indicating minimal recompete exposure in that window; the August 27, 2027, completion date on the $231.2 million BPA creates a material recompete cliff beyond the near term.

Takeda's federal pharmaceutical supply work serves the Department of Veterans Affairs across multiple regional networks, the Department of Justice Bureau of Prisons, the Defense Logistics Agency, the NIH Clinical Center, and the Department of Defense Medical Supply Chain. The company operates exclusively on firm fixed-price delivery orders and purchase orders drawn from pre-negotiated GSA schedule pricing, reflecting the single-source and specialized nature of its product portfolio. No teaming or sub-award activity is present in the recent award history; all performance is delivered directly from Takeda's two domestic facilities.